TESARO, Inc.
DelistedCIK 1491576fmd_04Z5XSTA5T7W1P9TR2WK78M22DManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2010 to Sep 30, 2018, 32 periods
| Line item | FY2011 | FY2012 | FY2013 | FY2014 | FY2015 | FY2016 | FY2017 |
|---|---|---|---|---|---|---|---|
| Total revenues | – | – | – | – | 4 | 58 | 223 |
| Cost of revenue | – | – | – | – | 0 | 1 | 41 |
| Gross profit | – | – | – | – | 4 | 57 | 182 |
| Research and development | 12 | 47 | 76 | 118 | 155 | 235 | 309 |
| Total operating expenses | 15 | 62 | 92 | 167 | 236 | 416 | 703 |
| Operating income | (15) | (62) | (92) | (167) | (232) | (358) | (480) |
| Interest expense | – | – | – | 4 | 15 | 16 | 20 |
| Interest and investment income | 0 | 0 | 0 | 0 | 0 | 1 | 4 |
| Other non-operating income (expense) | (1) | – | – | – | – | – | – |
| Income before taxes | – | (62) | (92) | (171) | (248) | (373) | (495) |
| Income tax expense | – | – | – | – | – | 1 | 1 |
| Net income from continuing operations | – | – | – | – | – | (374) | (496) |
| Net income | – | – | – | – | (248) | (374) | (496) |
| Net income to common shareholders | (16) | (62) | (92) | (171) | (248) | (374) | (496) |